SNN
Smith & Nephew·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Gap Up
Low Beta
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SNN
Smith & Nephew Plc
A biopharmaceutical company focused on the repair, regeneration and replacement of soft and hard tissue
Healthcare Equipment and Supplies
--
11/16/1999
New York Stock Exchange
18,060
12-31
Depository Receipts (Ordinary Shares)
Building 5, Croxley Park, Hatters Lane, Watford, Hertfordshire WD18 8YE
--
Smith & Nephew plc is a public limited company incorporated in England and Wales. The company offers a broad portfolio of differentiated products and services to meet often complex clinical needs, including digital and robotics, driving program innovation. The three franchises set product strategies, which are executed by sales organizations in the Americas, EMEA, and Asia Pacific. The company's sales team supports customers and works with the healthcare system to meet complex business and reimbursement requirements. The company supports safe and effective use of products, skills development and program innovation through the Academy's Medical Education Program. Build close relationships with clients to ensure a deep understanding of unmet clinical needs and changing financial and sustainability priorities in the healthcare system. Provide customer and franchise-focused innovation and R&D models for acquiring technologies that require further development and commercialization.
Earnings Call
Company Financials
EPS
SNN has released its 2019 Q2 earnings. EPS was reported at 0.35, versus the expected 0, beating expectations. The chart below visualizes how SNN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available


